ANTHRACYCLINE DERIVATIVES, A PROCESS FOR THE PRODUCTION THEREOF, A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AND THEIR USE AS MEDICAMENTS

Abstract: The present invention relates to novel anthracycline compounds, and a process for producing the same. The compounds have anti-tumor activities and can, therefore, be used as medicaments.

Description: Anthracvcline derivatives, a process for thr production thereof, a pharmaceutical composition containing the same and their use as medicaments The present invention relates to novel anthracycline compounds, a process for producing the same, and use of the same. Anthracycline compounds are important as cancer-control anti-biotics and several types of the compounds have already been proposed. The physiological activities of chemical substances largely depend on their chemical structures and anthracycline compounds are not an exception. It could be said that there exists a constant demand for developing new anthracycline compounds having unconventional types of, or substituents on, the aglycone and sugar portions. The invention provides, therefore, anthracycline compounds of the formula shown below or acid addition salts thereof: EMI1.1 wherein R1, R2, R3 and R4 represent any one of the eleven combinations listed in the following table: EMI2.1 <tb> No. <SEP> Compound <SEP> R1 <SEP> R2 <SEP> R3 <SEP> R4 <tb> <SEP> (1) <SEP> ditrisarubicin <SEP> D <SEP> H <SEP> OH <SEP> (I) <SEP> (V) <tb> <SEP> (2) <SEP> ditrisarubicin <SEP> E <SEP> H <SEP> OH <SEP> (II) <SEP> (II) <tb> <SEP> (3) <SEP> ditrisarubicin <SEP> F <SEP> H <SEP> OH <SEP> (I) <SEP> (VI) <tb> <SEP> (4) <SEP> ditrisarubicin <SEP> G <SEP> H <SEP> OH <SEP> (I) <SEP> (III) <tb> <SEP> (5) <SEP> ditrisarubicin <SEP> CR <SEP> H <SEP> @ <SEP> OH <SEP> , <SEP> <SEP> (IV) <SEP> (I) <SEP> <tb> <SEP> (6) <SEP> ditrisarubicin <SEP> GR <SEP> H <SEP> OH <SEP> (III) <SEP> (I) <tb> <SEP> (7) <SEP> ditrisarubicin <SEP> G/de-Ro <SEP> H <SEP> OH <SEP> (I) <SEP> (VII) <tb> <SEP> (8) <SEP> ditrisarubicin <SEP> GR/de-Ro <SEP> H <SEP> OH <SEP> (VII) <SEP> (I) <tb> <SEP> (9) <SEP> ditrisarubicin <SEP> B/10de-dF-CB <SEP> H <SEP> OH <SEP> (I) <SEP> (VIII) <tb> <SEP> (10) <SEP> ditrisarubicin <SEP> B/7de-dF-CB <SEP> | <SEP> H <SEP> OH <SEP> (VIII) <SEP> (I) <tb> <SEP> (II) <SEP> 1-hydroxyserirubicin <SEP> OH <SEP> H <SEP> (I) <SEP> (I <tb> wherein the symbols used for R3 and R4 represent the followina sugar chains: : (I) RN-dF-CB (II) RN-dF-CA EMI3.1 (III) RN-dF-Ro (IV) RN-Ro-Ac EMI3.2 @ @@-Rc-CA (VI) RN-Ro-Ro EMI4.1 (VI) RN-dF (VIII) RN EMI4.2 (RN: rhodosamine, dF: 2-deoxyfucose, CB: cinerulose B, CA: cinerulose A, Ac: aculose, Ro: rhodinose). The anthracycline compounds according to the present invention have the chemical structure represented by formula (I). They consist of eleven types according to the types of substituents R1 to R4 in formula (I) and how these substituents are combined. The anthracycline compouncs of the present invention have a dimethylamino group in the sugar portion and hence are capable of forming acid addition salts. Acids with which the compounds react to form addition salts include hydrohalogenic acids such as hydrochloric acid, as well as sulfuric acid and tartaric acid. The chemical structure of the anthracycline compounds according to the present invention were determined by the methods shown in the Experimental Examples given later in this specification. 3) Physicochemical properties Some of the physicochemical properties of the anthrocycline compounds according to the present invention are shown below. Table 1-1 EMI6.1 <SEP> Ditrisarubicin <SEP> D <SEP> Ditrisarubicin <SEP> E <SEP> Ditrisarubicin <SEP> F <SEP> Ditrisarubicin <SEP> Gu <tb> <SEP> (1) <SEP> (2) <SEP> (3) <SEP> (4) <tb> 1 <SEP> Appearance <SEP> red <SEP> powder <SEP> red <SEP> powder <SEP> red <SEP> powder <SEP> red <SEP> powder <tb> 2 <SEP> Elemental <tb> <SEP> analysis <SEP> (%) <tb> <SEP> (1) <SEP> Found <SEP> C: <SEP> 63,21 <SEP> H: <SEP> 6.89 <SEP> C: <SEP> 60.63 <SEP> H: <SEP> 7.31 <SEP> C: <SEP> 62.21 <SEP> H: <SEP> 7.02 <SEP> C: <SEP> 60.39 <SEP> H: <SEP> 7.26 <tb> <SEP> N: <SEP> 2.71 <SEP> N: <SEP> 2.52 <SEP> N: <SEP> 2.51 <SEP> N: <SEP> 2.21 <tb> <SEP> (2) <SEP> Calculated <SEP> C: <SEP> 61.74 <SEP> H: <SEP> 7.08 <SEP> C: <SEP> 60.80 <SEP> H: <SEP> 7.14 <SEP> C: <SEP> 61.63 <SEP> H: <SEP> 7.24 <SEP> C: <SEP> 60.80 <SEP> H: <SEP> 7.14 <tb> <SEP> N: <SEP> 2.40 <SEP> N: <SEP> 2.36 <SEP> N: <SEP> 2.39 <SEP> N: <SEP> 2.36 <SEP> O: <SEP> 29.69 <tb> <SEP> (for <SEP> C60H82N2O21) <SEP> (for <SEP> C60H82N2O22) <SEP> (for <SEP> C60H82N2O21) <SEP> (for <SEP> C60H82N2O22) <tb> 3 <SEP> Molecular <tb> <SEP> weight <tb> <SEP> (1) <SEP> FD-MS <SEP> m/z <SEP> 1167 <SEP> (M+H)+ <SEP> 1185 <SEP> (M+H)+ <SEP> 1169 <SEP> (M+H)+ <SEP> 1185 <SEP> (M+H)+ <tb> <SEP> (2) <SEP> Calcd.. <SEP> 1167.3 <SEP> 1185.3 <SEP> 1169.3 <SEP> 1185.3 <tb> 4 <SEP> mp <SEP> ( C) <SEP> 139 <SEP> # <SEP> 143 <SEP> 147 <SEP> # <SEP> 152 <SEP> 178 <SEP> # <SEP> 181 <SEP> 110 <SEP> # <SEP> 112 <tb> 5 <SEP> [&alpha;]D25 <SEP> Specific <SEP> +136 <SEP> +48 <SEP> +161 <SEP> +132 <tb> <SEP> rotation <SEP> (C <SEP> 0.05 <SEP> in <SEP> CHCl3) <SEP> (C <SEP> 0.05 <SEP> in <SEP> CHCl3) <SEP> (C <SEP> 0.05 <SEP> in <SEP> CHCl3) <SEP> (C <SEP> 0.05 <SEP> in <SEP> CHCl3) <tb> 6 <SEP> UV <SEP> absorption <SEP> (in <SEP> acidic <SEP> (in <SEP> acidic <SEP> (in <SEP> acidic <SEP> (in <SEP> acidic <tb> <SEP> spectrum <SEP> methanol) <SEP> methanol) <SEP> methanol) <SEP> methanol) <tb> <SEP> # <SEP> max <SEP> nm <SEP> (Ecm1%) <SEP> 254(240), <SEP> 290(69) <SEP> 254(215), <SEP> 292(66) <SEP> 254(227), <SEP> 290(68) <SEP> 254(219), <SEP> 290(67) <tb> <SEP> 495(130) <SEP> 530s(87) <SEP> 495(124), <SEP> 530s(81) <SEP> 495(126), <SEP> 530s(83) <SEP> 494(126), <SEP> 530s(83) <tb> <SEP> (in <SEP> alkaline <SEP> (in <SEP> alkaline <SEP> (in <SEP> alkaline <SEP> (in <SEP> alkaline <tb> <SEP> methanol) <SEP> methanol) <SEP> methanol) <SEP> methanol) <tb> <SEP> 241(343), <SEP> 295(64) <SEP> 241(308), <SEP> 298(59) <SEP> 241(334), <SEP> 298(64) <SEP> 242(325), <SEP> 298(62) <tb> <SEP> 568(143), <SEP> 607(127) <SEP> 568(135), <SEP> 607(121) <SEP> 568(140), <SEP> 607(123) <SEP> 565(138), <SEP> 605(125) <tb> Table 1-1 (continued) EMI7.1 <SEP> Ditrisarubicin <SEP> D <SEP> Ditrisarubicin <SEP> E <SEP> Ditrisarubicin <SEP> F <SEP> Ditrisarubicin <SEP> G <tb> 7 <SEP> IR <SEP> absorption <SEP> Fig. <SEP> 1 <SEP> Fig. <SEP> 3 <SEP> Fig. <SEP> 5 <SEP> Fig. <SEP> 8 <tb> <SEP> spectrum <tb> <SEP> (KBr <SEP> tab.) <tb> 8 <SEP> NMR <SEP> spectrum <SEP> Fig. <SEP> 2 <SEP> Fig. <SEP> 4 <SEP> Fig. <SEP> 6 <SEP> Fig. <SEP> 9 <tb> <SEP> 250 <SEP> MHz <SEP> 250 <SEP> MHz <SEP> 250 <SEP> MHz <SEP> 250 <SEP> MHz <tb> <SEP> (in <SEP> CDCl3) <SEP> (in <SEP> CDCl3) <SEP> (in <SEP> CDCl3) <SEP> (in <SEP> CDCl3) <tb> <SEP> TCL <SEP> *1 <tb> <SEP> 0.31 <SEP> 0.27 <SEP> 0.25 <SEP> 0.22 <tb> 9 <SEP> Rf <SEP> value <tb> <SEP> 100:5:0.1 <SEP> 100:5:0.1 <SEP> 100:5:0.1 <SEP> 100:5:0.1 <tb> <SEP> CHCl3:CH3OH: <tb> <SEP> conc. <SEP> NH3 <SEP> water <tb> <SEP> HPLC <SEP> *2 <tb> 10 <SEP> tR <SEP> value <SEP> 9.5 <SEP> min <SEP> 3.8 <SEP> min <SEP> 6.0 <SEP> min <SEP> 3.4 <SEP> min <tb> <SEP> acetonitrile: <tb> <SEP> 0.45% <SEP> ag. <SEP> 35/65 <SEP> 35/65 <SEP> 35/65 <SEP> 35/65 <tb> <SEP> phosphoric <SEP> acid <tb> 11 <SEP> Solubility <tb> <SEP> (1) <SEP> Soluble <SEP> chloroform, <SEP> chloroform, <SEP> chloroform, <SEP> chloroform, <tb> <SEP> ethyl <SEP> acetate, <SEP> ethyl <SEP> acetate, <SEP> ethyl <SEP> acetate, <SEP> ethyl <SEP> acetate, <tb> <SEP> methanol, <SEP> methanol, <SEP> methanol, <SEP> methanol, <tb> <SEP> acetonitrile, <SEP> acetonitrile, <SEP> acetonitrile, <SEP> acetonitrile, <tb> <SEP> pyridine, <SEP> pyridine, <SEP> pyridine, <SEP> pyridine, <tb> <SEP> dimethyl <SEP> dimethyl <SEP> dimethyl <SEP> dimethyl <tb> <SEP> sulfoxide <SEP> sulfoxide <SEP> sulfoxide <SEP> sulfoxide <tb> <SEP> (2) <SEP> Sparingly <SEP> water, <SEP> water, <SEP> water, <SEP> water, <tb> <SEP> soluble <SEP> petroleum <SEP> ether, <SEP> petroleum <SEP> ether, <SEP> petroleum <SEP> ether, <SEP> petroleum <SEP> ether, <tb> <SEP> n-hexane <SEP> n-hexane <SEP> n-hexane <SEP> n-hexane <tb> *1 On silica gel plate 60 F254 (product of Merck Co.) *2 Using Nucleosil 5C18 (Macherey-Nagel, Germany) in 4 .6# x 250 mm column. Table 1-2 EMI8.1 <SEP> Ditrisarubicin <SEP> Ditrisarubicin <SEP> Ditrisarubicin <SEP> Ditrisarubicin <tb> <SEP> CR <SEP> (5) <SEP> GR <SEP> (6) <SEP> G/de-Ro <SEP> (7) <SEP> GR/de-Ro <SEP> (8) <tb> 1 <SEP> Appearance <SEP> red <SEP> powder <SEP> red <SEP> powder <SEP> red <SEP> powder <SEP> red <SEP> powder <tb> 2 <SEP> Elemental <tb> <SEP> analysis <SEP> (%) <tb> <SEP> (1) <SEP> Found <SEP> C: <SEP> 61.05 <SEP> H: <SEP> 7.13 <SEP> C: <SEP> 60.44 <SEP> H: <SEP> 7.41 <SEP> C: <SEP> 60.61 <SEP> H: <SEP> 6.82 <SEP> C: <SEP> 60.39 <SEP> H: <SEP> 6.78 <tb> <SEP> N: <SEP> 2.38 <SEP> N: <SEP> 2.48 <SEP> N: <SEP> 2.37 <SEP> N: <SEP> 2.83 <tb> <SEP> (2) <SEP> Calculated <SEP> C: <SEP> 61.84 <SEP> H: <SEP> 6.92 <SEP> C: <SEP> 60.80 <SEP> H: <SEP> 7.14 <SEP> C: <SEP> 60.55 <SEP> H: <SEP> 6.96 <SEP> C: <SEP> 60.55 <SEP> H: <SEP> 6.96 <tb> <SEP> N: <SEP> 2.40 <SEP> N: <SEP> 2.36 <SEP> N: <SEP> 2.36 <SEP> N: <SEP> 2.61 <tb> <SEP> (for <SEP> C60H82N2O21) <SEP> (for <SEP> C60H82N2O22) <SEP> (for <SEP> C54H74N2O20) <SEP> (for <SEP> C54H74N2O20) <tb> 3 <SEP> Molecular <tb> <SEP> weight <tb> <SEP> (1) <SEP> FD-MS <SEP> m/z <SEP> 1165 <SEP> (M+H)+ <SEP> 1184 <SEP> (M+H)+ <SEP> 1071 <SEP> (M+H)+ <SEP> 1071 <SEP> (M+H)+ <tb> <SEP> (2) <SEP> Calcd.. <SEP> 1165.3 <SEP> 1185.3 <SEP> 1071.2 <SEP> 1071.2 <tb> 4 <SEP> mp <SEP> ( C) <SEP> 182 <SEP> # <SEP> 184 <SEP> 168 <SEP> # <SEP> 170 <SEP> 191 <SEP> # <SEP> 195 <SEP> 191 <SEP> # <SEP> 194 <tb> 5 <SEP> [&alpha;]D25 <SEP> Specific <SEP> +199 <SEP> +167 <SEP> +176 <SEP> +194 <tb> <SEP> rotation <SEP> (C <SEP> 0.06 <SEP> in <SEP> CHCl3) <SEP> (C <SEP> 0.1 <SEP> in <SEP> CHCl3) <SEP> (C <SEP> 0.05 <SEP> in <SEP> CHCl3) <SEP> (C <SEP> 0.05 <SEP> in <SEP> CHCl3) <tb> 6 <SEP> UV <SEP> absorption <tb> <SEP> spectrum <SEP> (in <SEP> acidic <SEP> (in <SEP> acidic <SEP> (in <SEP> acidic <SEP> (in <SEP> acidic <tb> <SEP> methanol) <SEP> methanol) <SEP> methanol) <SEP> methanol) <tb> <SEP> # <SEP> max <SEP> nm <SEP> (Ecm1%) <SEP> 253(265),290(92) <SEP> 254(219),290(67) <SEP> 254(256),290(75) <SEP> 254(256),290(72) <tb> <SEP> 495(125),530s(76) <SEP> 494(120),530S(83) <SEP> 495(142),530s(93) <SEP> 495(136),530s(90) <tb> <SEP> (in <SEP> alkaline <SEP> (in <SEP> alkaline <SEP> (in <SEP> alkaline <SEP> (in <SEP> alkaline <tb> <SEP> methanol) <SEP> methanol) <SEP> methanol) <SEP> methanol) <tb> <SEP> 240(410),295(85) <SEP> 240(325),298(62) <SEP> 242(374),300(67) <SEP> 241(370),300(67) <tb> <SEP> 566(134),605(119) <SEP> 565(132),605(118) <SEP> 565(159),605(141) <SEP> 565(151),605(133) <tb> Table 1-2 (continued) EMI9.1 <SEP> Ditrisarubicin <SEP> Ditrisarubicin <SEP> Ditrisarubicin <SEP> Ditrisarubicin <tb> <SEP> CR <SEP> (5) <SEP> GR <SEP> (6) <SEP> G/de-Ro <SEP> (7) <SEP> GR/de-Ro <SEP> (8) <tb> 7 <SEP> IR <SEP> absorption <tb> <SEP> spectrum <SEP> Fig. <SEP> 11 <SEP> Fig. <SEP> 13 <SEP> Fig. <SEP> 15 <SEP> Fig. <SEP> 17 <tb> <SEP> (KBr <SEP> tab.) <tb> 8 <SEP> NMR <SEP> spectrum <SEP> Fig. <SEP> 12 <SEP> Fig. <SEP> 14 <SEP> Fig. <SEP> 16 <SEP> Fig. <SEP> 18 <tb> <SEP> 400 <SEP> MHz <SEP> 400 <SEP> MHz <SEP> 400 <SEP> MHz <SEP> 400 <SEP> MHz <tb> <SEP> (in <SEP> CDCl3) <SEP> (in <SEP> CDCl3) <SEP> (in <SEP> CDCl3) <SEP> (in <SEP> CDCl3) <tb> 9 <SEP> TLC <SEP> 0.37 <SEP> 0.21 <SEP> 0.38 <SEP> 0.35 <tb> <SEP> CHCl3:CH3OH: <tb> <SEP> 100:5:0.1 <SEP> 100:5:0.1 <SEP> 100:10:0.05 <SEP> 100:10:0.05 <tb> <SEP> conc. <SEP> NH3 <SEP> water <tb> <SEP> HPLC <SEP> *2 <tb> 10 <SEP> tR <SEP> value <SEP> 11.5 <SEP> min <SEP> 3.9 <SEP> min <SEP> 3.0 <SEP> min <SEP> 3.8 <SEP> min <tb> <SEP> acetonitrile: <tb> <SEP> 0.45% <SEP> 35/65 <SEP> 35/65 <SEP> 35/65 <SEP> 35/65 <tb> <SEP> phosphoric <tb> <SEP> acid <tb> 11 <SEP> Solubility <tb> <SEP> (1) <SEP> soluble <SEP> chloroform, <SEP> chloroform, <SEP> chloroform, <SEP> chloroform, <tb> <SEP> ethyl <SEP> acetate, <SEP> ethyl <SEP> acetate, <SEP> ethyl <SEP> acetate, <SEP> ethyl <SEP> acetate, <tb> <SEP> methanol, <SEP> methanol, <SEP> methanol, <SEP> methanol, <tb> <SEP> acetonitrile, <SEP> acetonitrile, <SEP> acetonitrile, <SEP> acetonitrile, <tb> <SEP> pyridine, <SEP> pyridine, <SEP> pyridine, <SEP> pyridine, <tb> <SEP> dimethyl <SEP> dimethyl <SEP> dimethyl <SEP> dimethyl <tb> <SEP> sulfoxide <SEP> sulfoxide <SEP> sulfoxide <SEP> sulfoxide <tb> <SEP> (2) <SEP> sparingly <SEP> water, <SEP> water, <SEP> water, <SEP> water, <tb> <SEP> soluble <SEP> petroleum <SEP> ether, <SEP> petroleum <SEP> ether, <SEP> petroleum <SEP> ether, <SEP> petroleum <SEP> ether, <tb> <SEP> n-hexane <SEP> n-hexane <SEP> n-hexane <SEP> n-hexane <tb> *1, *2: See the fotnotes to Table 1-1. Table 1-3 EMI10.1 <SEP> Ditrisarubicin <SEP> Ditrisarubicin <SEP> 1-hydroxyserirubicin <tb> <SEP> B/10de-dF-CB <SEP> (9) <SEP> B/7de-dF-CB <SEP> (10) <tb> 1 <SEP> Appearance <SEP> red <SEP> powder <SEP> red <SEP> powder <SEP> red <SEP> powder <tb> 2 <SEP> Elemental <tb> <SEP> analysis <SEP> (%) <tb> <SEP> (1) <SEP> Found <SEP> C: <SEP> 61.03 <SEP> H: <SEP> 6.39 <SEP> C: <SEP> 61.13 <SEP> H:7.03 <SEP> C: <SEP> 60.83 <SEP> H: <SEP> 7.12 <tb> <SEP> N: <SEP> 2.64 <SEP> N: <SEP> 2.84 <SEP> N: <SEP> 2.27 <tb> <SEP> (2) <SEP> Calculated <SEP> C: <SEP> 61.27 <SEP> H: <SEP> 6.86 <SEP> C: <SEP> 61.27 <SEP> H: <SEP> 6.86 <SEP> C: <SEP> 61.01 <SEP> H: <SEP> 6.83 <tb> <SEP> N: <SEP> 2.98 <SEP> N: <SEP> 2.98 <SEP> N: <SEP> 2.37 <tb> <SEP> (for <SEP> C48H64N2O17) <SEP> (for <SEP> C48H64N2O17) <SEP> (for <SEP> C60H80N2O22) <tb> 3 <SEP> Molecular <tb> <SEP> weight <tb> <SEP> (1) <SEP> FD-MS <SEP> m/z <SEP> 941 <SEP> (M+H)+ <SEP> 941 <SEP> (M+H)+ <SEP> 1181 <SEP> (M+H)+ <tb> <SEP> (2) <SEP> Calcd. <SEP> 941.0 <SEP> 941.0 <SEP> 1181.3 <tb> 4 <SEP> mp <SEP> ( C) <SEP> 191 <SEP> # <SEP> 195 <SEP> 189 <SEP> # <SEP> 192 <SEP> 189 <SEP> # <SEP> 192 <tb> 5 <SEP> [&alpha; ;]D25 <SEP> Specific <tb> <SEP> +291.2 <SEP> +345.5 <SEP> +1 <SEP> (#2) <tb> <SEP> rotation <tb> <SEP> (C <SEP> 0.05 <SEP> in <SEP> CHCl3) <SEP> (C <SEP> 0.05 <SEP> in <SEP> CHCl3) <SEP> (C <SEP> 0.1 <SEP> in <SEP> CHCl3) <tb> 6 <SEP> UV <SEP> absorption <SEP> (in <SEP> acidic <SEP> (in <SEP> acidic <SEP> (in <SEP> acidic <tb> <SEP> spectrum <SEP> methanol) <SEP> methanol) <SEP> methanol) <tb> <SEP> 255(270),292(81) <SEP> 255(204),292(85) <SEP> 256(190),290(66) <tb> <SEP> # <SEP> max <SEP> nm <SEP> (Ecm1%) <SEP> 495(153),530s(107) <SEP> 496(165),530s(108) <SEP> 493(119),513s(89) <tb> <SEP> (in <SEP> alkaline <SEP> (in <SEP> alkaline <SEP> (in <SEP> alkaline <tb> <SEP> methanol) <SEP> methanol) <SEP> methanol) <tb> <SEP> 241(439),298(78) <SEP> 240(425),298(73) <SEP> 238(373),290(69) <tb> <SEP> 568(179),610(153) <SEP> 568(176),610(159) <SEP> 565(145),606(139) <tb> Table 1-3 (continued) EMI11.1 <SEP> Ditrisarubicin <SEP> Ditrisarubicin <SEP> 1-hydroxyserirubicin <tb> <SEP> B/10de-dF-CB <SEP> (9) <SEP> B/7de-dF-CB <SEP> (10) <SEP> (11) <tb> 7 <SEP> IR <SEP> absorption <tb> <SEP> spectrum <SEP> Fig. <SEP> 19 <SEP> Fig. <SEP> 21 <SEP> Fig. <SEP> 24 <tb> <SEP> (KBr <SEP> tab.) <tb> 8 <SEP> NMR <SEP> spectrum <SEP> Fig. <SEP> 20 <SEP> Fig. <SEP> 22 <SEP> Fig. <SEP> 25 <tb> <SEP> 400 <SEP> MHz <SEP> (in <SEP> CHCl3) <SEP> 400 <SEP> MHz <SEP> (in <SEP> CDCl13) <SEP> 400 <SEP> MHz <tb> 9 <SEP> TLC <SEP> *1 <SEP> Rf <SEP> value <SEP> 0.30 <SEP> 0.23 <SEP> 0.41 <tb> <SEP> CHCl3:CH3OH: <tb> <SEP> 100:5:0.1 <SEP> 100:5:0.1 <SEP> 100:5:0.1 <tb> <SEP> conc. <SEP> NH3 <SEP> water <tb> 10 <SEP> HPLC <SEP> *2 <SEP> tR <SEP> value <SEP> 1.25 <SEP> min <SEP> 20.8 <SEP> min <SEP> 6.3 <SEP> min <tb> <SEP> acetonitrile: <SEP> 0.45% <SEP> ag. <tb> <SEP> 25/75 <SEP> 25/75 <SEP> 35/65 <tb> <SEP> phosphoric <SEP> acid <tb> 11 <SEP> Solubility <tb> <SEP> (1) <SEP> soluble <SEP> chloroform, <SEP> chloroform, <SEP> chloroform, <tb> <SEP> ethyl <SEP> acetate, <SEP> ethyl <SEP> acetate, <SEP> ethyl <SEP> acetate, <tb> <SEP> methanol, <SEP> methanol, <SEP> methanol, <tb> <SEP> acetonitrile, <SEP> acetonitrile, <SEP> acetonitrile, <tb> <SEP> pyridine, <SEP> pyridine, <SEP> pyridine, <tb> <SEP> dimethyl <SEP> sulfoxide <SEP> dimethyl <SEP> sulfoxide <SEP> dimethyl <SEP> sulfoxide <tb> <SEP> (2) <SEP> sparingly <SEP> water, <SEP> water, <SEP> water, <tb> <SEP> soluble <SEP> petroleum <SEP> ether, <SEP> petroleum <SEP> ether, <SEP> petroleum <SEP> ether, <tb> <SEP> n-haxane <SEP> n-hexane <SEP> n-hexane <tb> *1, *2: See the footnotes to Table 1-1. res@@@@ @@@@@ @thracycline compounds of the present invention can only be prepared by cultivating microorganisms. However, they could be prepared by chemical or microbiological modificaticns of related compounds, or even by total synthesis from such related compounds. If the anthracycline compounds of the present inventior are prepare by cultivation of microorganisms, the strain to be used is selected from among the microorganisms of the genus Strettomyces which are capable of producing the anthracycline compounds of the present invention. For example, -ne strain Streptomyces cvaneus MS-344-hF 49 has the ability tc produce the anthracycline compounds of the present invention. Other suitable strains may be isolated from the nature by techniques conventionally used in the isolation of anti-biotics producing microorganisms. Strain S. cyaneus MG 344-hF 49 and other microorganisms capable of producing the anthracycline compounds of the present invention could be expose to radio-active radiation or given other treatements for the purpose of enhancing their abilitv to produce the anthracycline compounds. The strain MG 344-hF 49 has the following characteristics: StreDtomyces cyaneus MG 344-hF d,o is an actinomycetes that was isolated in August 1980 from the soil in the premises of the Institute of Microbial Chemistry. This strain was deposited with the Fermentation Research Institute, Agency of Industrial Science and Technology on June 28, 1982 and given the number FEWI BP-314. (1) Mycological Properties A. Morphology Under microscopic observation, strain MG 344-hF 49 forms spiny cr spiral aerial mycellia from branched substrate mycellia, but no whirl is observed. -Each mature spore chain consists of at least 10 spores, The spore size is roughly in the range of 0.4 - 0.6 x 0.8 - 1.0 urn, and the spore surface is spiny. B. Growth on various media The designations in brackets used in the color indication given in the following description are in accordance with Color Harmony Manual published by Container Corporation of America. (a) Ciniclose-nitrate agar medium (cultured at 270C) A white thin film of aerial mycellia adheres to a growth of dull purplish red 19 le, Raspberry]. Purplish soluble pigment. (b) Glucose-asparagine agar medium (cultured at 270C) Light bluish gray [18 ec, Lt Aqua] aerial mycellia adhere to a yellowish red t6 la, Lt Coral Red - 6 pc, paprika] growth. Reddish soluble pigment. (c) Glycarine-asparagine agar medium (ISp-medium 5: cultured at 270C) Aerial mycellia having colors in the range of from white thru gray white to light bluish gray adhere to a grayish purple [9 lg, Rose Plum] growth. No soluble pigment observed. (d) Starch-inorganic salt agar medium (ISP-medium 4: cultured at 27 C) Aerial mycellia having colors in the range of from white to grayish blue green [19 ie, Turquoise Green] adhere to a pale pink growth. Soluble pigment with a pink tinge. (e) Tyrosine agar medium (ISO-medium 7: cultured at 270C) Aerial mycellia having colors in the range of from gray white to light bluish gray adhere to a growth ranging in color from, light brown to dark thrown. Soluble pigment with a light brownish tinge. (f) Nutrient agar medium (cultured at 270C) Aerial mycellia having a light purplish gray color adhere to a grayish red purple [8 le, Rose Wine] growth. A brown soluble pigment was produced. (g) Yeast-malt agar medium (ISP medium 2: cultured at 27 C) Aerial mycellia having colors in the range of from white thru purplish white to bluish white adhere to a grayish red purple [9 ne, Raspberry] growth. No soluble pigment observed. (h) Oatmeal agar medium (ISP-medium 3: cultured at 270C) Aerial mycellia having colors in the range of bluish gray to grayish blue green [21 li, Dk Jade Gray] adhere to a growth having colors ranging from pale pink to dull purple [10 pc, Fuchsia Purple3. Soluble pigment with a red tinge. (i) Glycerine-nitrate agar medium (cultured at 270C) White aerial mycellia slightly adhere to a grayish purple [9 le, Raspberry] growth. Soluble pigment with a purplish tinge. (j) Starch agar medium (cultured at 270C) Growth with a dull grayish red purple color [7 1/2 le, Rose Wine]. No aerial mycellia. Soluble pigment with a purplish tinge. (k) Calcium malate agar medium (culturec at 270C) A thin film of white aerial mycellia adhere to a pale purple growth. Soluble pigment with a purplish tinge. (Q) Cellulose (synthetic solution added with filter paper, cultured at 270C) No growth. (m) Gelatin stab culture With simple gelatin medium (cultured at 200C), white aerial mycellia slightly adhere to a pale yellow growth. Brown soluble pigment is produced. With glucose-peptonegelatin medium (cultured at 27 C), pink white aerial mycellia ahere to a colorless to pale yellow-growth. Dark brown soluble pigment is produced. (n) Skim milk (cultured at 370C) White aerial mycellia adhere slightly to a pink to grayish red growth. Soluble pigment with a brown tinge. (2) Physiological Properties A. General descriptior a. Growth temperature range Tests on glucose-asparagine agar at 200C, 24 C, 270C, 300C, 370C and 500C showed that the strain grew at all temperatures except for 50 C. Optimum temperature would approximately be in the range of 30 - 370C. b. Liquefaction of gelatin (15% simple gelatin: cultured at 200C, glucose-peptone-gelatin: cultured at 270C) With the simple gelatin, liquefaction started approximately on the fifth day of the cultivation. With the glucose-peptone-gelatin, no liquefaction took place even when two weeks passed after the start of the cultivation, and weak liquefaction was observed approximately on the third week. The degree of liquefaction was from moderate to weak with the simple gelatin, and weak with the glucose-peptonegelatin. c. Hydrolysis of starch (cultured at 270C on either starchinorganic agar medium or starch agar medium) Starch hydrolysis was found to occur on about the third day of the cultivation, and its degree was from moderate to weak. d. Coagulation and peptonization of skim milk (cultivation on skim milk at 370C) Coagulation started to occur on about the third day of the cultivation, and on about the seventh day, coagulation was completed and peptonizatior. started, The degree of peptonization was moderate. e. Formation of melamine-like pigment (cultured at 270C on either Tryptone-yeast-broth (ISP-medium 1), peptone-yeastiron agar (ISP-medium 6) or tyrosine agar (ISO-medium 7)) Pigment formation was observed on each medium. f. Utilization of carbon sources (cultured at 270C on Pridham-Gottlieb agar medium (ISP-medium 9)) The strain grew by utilizing any of the following carbon sources: L-arabinose, D-xylose, D-glucose, D-fructose, sucrose, inositol, L-rhamnose, raffinose and D-mannitol. g. Dissolution of calcium malate (calcium malate agar: cultured at 270C) Calcium malate was found to dissolve on the periphery of the growth approximately on the seventh day of the cultivation, but its degree was rather weak. h. Reduction of nitrate (aqueous peptone containing 1 08 potassium nitrate (ISP-medium 8): cultured at 270C) Positive Conclusion and Identification of New Strain To summarize: Strain MG 344-hF 9 belongs to the genus Streetomyces and 2,6-diaminopimelic acid contained in the cell wall is of the L,L-type. No sporandia observed. Aerial mycelia form a spiral but not a whirl. The spore surface is spiny. With various media, aerial mycellia having colors in the range of from white thru light bluish gra? to grayish blue greet adhere to a growth ranging in color from grayish red purple to yellowish red . Purplish or reddish soluble pigment formed. The reverse side of the growth serves as a pH indicator, and its color changes from purplish to bluish purple or blue upon addition of IN Nave. Melamine-like pigment is positive and the proteolytic power is from moderate to weak. The degree of starch hydrolysis is also from moderate to weak. The screening of the known strains on the basis of these data shows that Streptomyces cyaneus would be most closely related to strain 344-hF 49 (International Journal of Systematic Bacteriology, 22, p. 290, 1972 (Reference 1), Waksman; The Actinomycetes, 2, p. 199, 1961 (Reference 2), Bergey's Manual of Determinative Bacteriology, 7th ed., p. 757, 1957 and supra, 8th ed., p. 822, 1974 (Reference 3)). The properties of strain MG 344-hF 49 are compared in the following table with those of Streptomyces Cyaneus listed in the literature cited. Table 2 Streptomyces cyaneus MG 344-hF 4 ISP 5108 Form of aerial mycellia spiral spiral Spore surface spiny spiny Color of aerial mycellia white - light pale blue bluish gray - bluish gray grayish blue green Color of growth pale pink - dark grayish grayish red purple blue - dark grayish purple Soluble pigment from (-) to from (-) to purplish, purplish or sometimes bluish reddish Formation of melamine-like pigment + + Starch hydrolysis + moderate to weak + weak * Milk coagulation + + Milk peptonization + + Table 2 (continued) Streptomyces cyaneus MG 344-hF 49 ISP 5108 Gelatin liguefaction + moderate to weak + strong * Reduction of nitrate + - * Utilizatiom of carbon sources D-glucose + + L-arabinose + + D-xylose + + D-fructose + + Sucrose + + Inositol + + L-rhamnose + + Raffinose + + D-mannitol + + pH indicator + + * According to References 2 and 3. As shown in Table 2, strain MG 344-hF 49 and Streptomyces cyaneus are substantially the same in their properties except for the reduction of nitrate. However, the reduction of nitrate is not considered a reliable parameter for identifying a certain microorganism as an Actinomyces and cannot be used to distinguish between the two strains. Therefore, strain MG 344-hF 49 is considered to be most closely related to Stretomyces cyaneus, and for this reason, the present inventors identified strain MG 344-hF 49 as Stretornyces cvaneus MG 344-hF 49. The anthracycline compounds of the present invention can be produced by aerobically cultivating on a suitable medium the microorganism of the genus Strettomvces that are capable of producing the anthracycline compounds of the present invention, and by subsequently collecting the final compound from the culture. The medium used may contain any of the nutrient sources that can be utilized b the microorganism capable of producing the anthracycline compounds of the present invention. Specific examples of the nutrient sources include carbon sources such as glycerine, glucose, sucrose, maltose, dextrin, starch, as well as fats and oils; nitrogen sources such as organic substances like soybean meal, cotton seed oil cake, meat extract, peptone, dry yeast, yeast extract and corn steep liquor, as well as inorganic substances like ammonium salts and nitrate salts typified by ammonium sulfate, sodium nitrate and ammonium chloride. If necessary, inorganic salts such as sodium chloride, potassium chloride, phosphate salts and heavy metal salts may be added. In order to inhibit foaming that may occur during fermentation, a suitable defoamer such as silicone may be optionally added according to the conventional technique. As in the case of common practice in the production of antibiotics, aerobic liquid submerged culture is the most appropriate method for cultivating the anthracycline producing microorganism. The cultivation temperature is suitably in the range of 20 to 350C, with 25 - 300C being particularly preferred. Whether this method depends on shake culture or aerated spinner culture, the yield of the anthracycline compound of the present invention reaches a maximum in three to seven days. In this manner, a culture having the anthracycline compound of the present invention accumulated therein can be obtained. Part of the anthracycline compound may exist in the cultured cells, but the greater part of it is contained in the culture filtrate. Any method that suits the specific purpose of the present invention may be used to recover the desired anthracycline compound from the thusly obtained culture. One technique is based on the principles of extraction; stated specifically, the anthracycline compound in the culture filtrate may be extracted with a water-immiscible ditrisarubicin dissolving solvent (see the literature cited above), such as ethyl acetate, butyl acetate, chloroform or butanol (high extraction efficiency is achieved if the culture filtrate is neutral to weakly basic), and if the anthracycline compound is within the cultured cells, the latter may be collected by filtration, centrifugation or any other suitable method, and the desired compound may be recovered by treating the collected cells with ethyl acetate, chloroform, methanol, ethanol, butanol, acetone, methyl ethyl ketone, aqueous hydrochloric acid, aqueous acetic acid, or the like. The culture may be directly subjected to such extraction treatments without separating the cells. The cells may be subjected to extraction after homogenization. Another possible extraction technique is the countercurrent distribution method. Another method for recovering the anthracycline compounds of the present invention from the culture is based on the principles of adsorption. An already liquid substance such as the culture filtrate which contains the anthracycline compound of the present invention, or the extract obtained by the extraction techniques shown above is subjected to column chromatography, liquid chromatography or other adsorption techniques using a suitable adsorbent such as activated carbon, alumina, silica gel or "Cephadex LH 20" (Pharmacia Co.); the adsorbate is subsequently eluted to recover the desired anthracycline compound of the present invention. The thusly obtained solution of the anthracycline compound of the present invention is concentrated to dryness under vacuum, thereby giving a crude sample of the end anthracycline compound as a red powder. The crude sample is purified by repeating the necessary times the extraction and adsorption procedures shown above, which may be combined as rquired. If necessary, recrystallization may be performed. For example, column chromatography using an absorbent such as silica gel, Cephadex LE 20e, a weakly acidic ion exchange resin or Diaion HP 20 (product of Mitsubishi Chemicals Industries Limited), or a gel filtering agent may be performed in combination with liquid chromatography (countercurrent distribution), high-pressure liquid chromatography or thin-layer chromatography using a suitable solvent. Stated more specifically, a crude powder of the anthracycline compound of the present invention is dissolved in a small amount of chloroform, and the solution is passed through a silica gel column. By elution with a suitable solvent, effluents containing the respective effective components are obtained. The desired active fractions are collected and concentrated under vacuum. By subsequent thin-layer chromatography, each of the end components can be obtained as a substantially pure product. For further purification, high-pressure liquid chromatography or crystallization from a suitable solvent may be performed. The anthracycline compounds according to the present invention have the activity of inhibiting the growth of leukemic cells and the anti-tumor activity, so they are useful as medicines. Determination of Chemical Structure I. Determining the structures of ditrisarubicins An outline for the procedure of determining the structures of ditrisarubicin D, E, F, G, CR, GR, G/d-Rc, GR/de-Ro, B/l0 de-dF-CB and B/7 de-dF-C3 (hereunder collectively referred to as DTR-X) is shown in Fig. 26, wherein RN represents rhodosamine and R1, R2, R3, R4, R5 and R6 respective sugars. In the following description, the symbols in Fig. 26 are used to identify the respective compounds. DTR-X (I) was completely hydrolyzed by heating in Q.1N HCZ at 85eC for 30 minutes. In such case, red aglycone (2) and respective sugars were obtained. Based on the Rf value with TLC on silica gel, W absorption spectra, mass spectrum (m/z 386 (M) ) and H-NMR spectrum, (2) was identified as B-rhodomycinone. The liquid hycrolyzates were neutralized with silver carbonate, developed on silica gel TLC with a mixture of n-butanol/acetic acid/water (4:1:1) and subjected to color reaction with p-anisaldehyde. The Rf values and color changes were used as identification means. The constituents sugars of DTR-X (1) and the parent peaks obtained in FD-mass spectra are shown in Table 3, wherein ++, + and - represent color changes from the result obtained with the hydrolyzate of control ditrisarubicin B (DTR-B). Table 3 EMI27.1 <SEP> FD <SEP> - <SEP> MS <SEP> Constituent <SEP> sugars <SEP> * <tb> <SEP> DTR-X <SEP> (1) <SEP> m/z <SEP> rhodosamine <SEP> 2-deoxyfucose <SEP> rhodinose <SEP> cinerulose <SEP> cinerulose <tb> DTR-D <SEP> 1167 <SEP> (M+H)+ <SEP> ++ <SEP> + <SEP> + <SEP> + <SEP> + <tb> DTR-E <SEP> 1185 <SEP> (M+H)+ <SEP> ++ <SEP> ++ <SEP> - <SEP> ++ <SEP> DTR-F <SEP> 1169 <SEP> (M+H)+ <SEP> ++ <SEP> + <SEP> ++ <SEP> - <SEP> ++ <tb> DTR-G <SEP> 1185 <SEP> (M+H)+ <SEP> ++ <SEP> ++ <SEP> + <SEP> - <SEP> + <tb> DTR-CR <SEP> 1165 <SEP> (M+H)+ <SEP> ++ <SEP> + <SEP> + <SEP> - <SEP> ++ <SEP> ** <tb> DTR-GR <SEP> 1184 <SEP> (M)+ <SEP> ++ <SEP> ++ <SEP> + <SEP> - <SEP> + <tb> DTR-G/de-Ro <SEP> 1071 <SEP> (M+H)+ <SEP> ++ <SEP> ++ <SEP> - <SEP> - <SEP> + <tb> DTR-GR/de-Ro <SEP> 1071 <SEP> (M+H)+ <SEP> ++ <SEP> ++ <SEP> - <SEP> - <SEP> + <tb> DTR-B/10de-dF-CB <SEP> 941 <SEP> (M+H)+ <SEP> ++ <SEP> + <SEP> - <SEP> - <SEP> + <tb> DTR-B/7de-dF-CB <SEP> 941 <SEP> (M+H)+ <SEP> ++ <SEP> + <SEP> - <SEP> - <SEP> + <tb> DTR-B <SEP> 1181 <SEP> (M+H)+ <SEP> ++ <SEP> ++ <SEP> - <SEP> - <SEP> ++ <tb> * : ++, + and - represent respective color changes. ** : 1H-NMR spectrum shows that DTR-CR has a molecule each of aculose and cinerulose B. When (1) was heated in D.1N HCt at 700C for 20 minutes, c@@pound (3) resulted in each case. Upon complete hydrolysis, (3) gave ss-rhodomycinone (2) and rhodosamine. Compound (3) gave a parent peak at m/z 700 (M) -in FD-mass spectrum. Based cr this information taken together with the results of 1H-NMR spectrum, compound (3) was found to be ss-rhodomycine II having a @olecule of rhodosamine bonded to each of 7- and 10-positions (@etrahedron Lett., 1969, 415-419, 1969). It therefore became c-ear that all variants of DTR-X (1) has ss-rhodomycine II in their partial structure. When compound (1) was reduced catalytically at ordinary temperature and pressure for 10 - 30 minutes in the presence of 5% Pd/BaS03, compound (4) was obtained. when compound (4) was completely hydrolyzed in 0.lN HCl, red aglycone (5) and various sugars formed in each case. Based on the Rf value with TLC on silica gel, UV absorption spectra, mass spectrum (m/z 370 (M) +) and E R spectrum, (5) was identified as y-rhodomycinone. Identification of the sugars was made on the basis of Rf values on silica gel TLC a=d color changes. The constituent sugars of the reduction decomposition product (4) of DTR-X (1) (the product is hereunder referred to as DTR-X/H2) and the parent peaks in FD-mass spectra therefor are shown in Table 4. Table 4 EMI29.1 <SEP> FD <SEP> - <SEP> MS <SEP> Constituent <SEP> sugars <SEP> * <tb> <SEP> DTR-X/H2 <SEP> (4) <SEP> m/z <SEP> rhodosamine <SEP> 2-deoxyfucose <SEP> rhodinose <SEP> cinerulose <SEP> cinerulose <tb> DTR-D/H2 <SEP> 754 <SEP> (M+H)+ <SEP> + <SEP> - <SEP> + <SEP> + <SEP> DTR-E/H2 <SEP> 770 <SEP> (M+H)+ <SEP> + <SEP> + <SEP> - <SEP> + <SEP> DTR-F/H2 <SEP> 756 <SEP> (M+H)+ <SEP> + <SEP> - <SEP> ++ <SEP> - <SEP> DTR-G/H2 <SEP> 772 <SEP> (M+H)+ <SEP> + <SEP> + <SEP> + <SEP> - <SEP> DTR-CR/H2 <SEP> 768 <SEP> (M+H)+ <SEP> + <SEP> + <SEP> - <SEP> - <SEP> + <tb> DTR-GR/H2 <SEP> 768 <SEP> (M+H)+ <SEP> + <SEP> + <SEP> - <SEP> - <SEP> + <tb> DTR-G/de-Ro/H2 <SEP> 658 <SEP> (M+H)+ <SEP> + <SEP> + <SEP> - <SEP> - <SEP> DTR-GR/de-Ro/H2 <SEP> 768 <SEP> (M+H)+ <SEP> + <SEP> + <SEP> - <SEP> - <SEP> + <tb> DTR-B/10de-dF-CB/H2 <SEP> 527 <SEP> (M)+ <SEP> + <SEP> - <SEP> - <SEP> - <SEP> DTR-B/7de-dF-CB/H2 <SEP> 768 <SEP> (M+H)+ <SEP> + <SEP> + <SEP> - <SEP> - <SEP> + <tb> * : ++, + and - represent respective color changes. When DTR-X/H2 (4) was partially hydrolyzed in 0.1N HCl by heating at 700C for 10 minutes, compound (6) resulted in each case. Upon complete hydrolysis, (6) gave y-rhodonomycine (5) and rhodosamine, with a parent peak appearing at m/z 527 (M) + in FD-mass spectrum. Analysis by 1H-NMR spectrum suggested a structure wherein a molecule of rhodosamine was bonded to (5). Based on these data, compound (6) was identified as y-rhodomycine I (Naturwissenshaften, 48, 717, 1961). It is therefore concluded that each variant of (4) contains #-rhodomycine I in its partial structure. Figs. 27 to 33 are 1H-NMR charts for DTR-D/H2, E/H2, F/H2, G/H2, CR/H2, G/de-Ro/H2 and B/10 de-dF-CB/H2. Corresponding 1H-NMR spectra for DTR-GR/H2, GR/de-Ro/H2 and B/7 dedF-CB/H2 are omitted since they are the same as that for DTR-CR/H2. These data show that DTR-X/H2 (4) variants are compounds wherein the sugar chains listed in Table 5 are bonded to y-rhodomycinone (5) at 10-position. The data in Tables 3 and 5, as well as the 1E IR spectrum charts in Figs. 2, 4, 6, 9, 12, 14, 16, 1S, 20 and 22 support the conclusion that the respective variants of DTR-X (1) have the structures shown in Table 6. Table 5 EMI31.1 <tb> <SEP> DTR-X/H2 <SEP> (4) <SEP> gugar <SEP> chains <SEP> * <tb> DTR-D/H2 <SEP> (V) <tb> DTR-E/H2 <SEP> (II) <tb> DTR-F/H2 <SEP> (VI) <tb> DTR-G/H2 <SEP> (III) <tb> DTR-CR/H2 <SEP> (I) <tb> DTR-GR/H2 <SEP> (I) <tb> DTR-G/de-Ro/H2 <SEP> (VII) <tb> DTR-GR/de-Ro/H2 <SEP> (I) <tb> DTR-B/10de-dF-CB/H2 <SEP> (VIII) <tb> DTR-B/7de-dF-CB/H2 <SEP> (I) <tb> * For the meanings of the respective symbols, see Fig. 36. Table 6 Structures of respective ditrisarubicines EMI32.1 EMI32.2 <tb> <SEP> Compound <SEP> Sugar <SEP> chains <tb> <SEP> (1) <SEP> R1 <SEP> R2 <tb> <SEP> (1) <SEP> DTR-D <SEP> I <SEP> (I) <SEP> (V) <tb> <SEP> (2) <SEP> DTR-E <SEP> (II) <SEP> (II) <tb> <SEP> (3) <SEP> DTR-F <SEP> (I) <SEP> (VI) <tb> <SEP> (4) <SEP> DTR-G <SEP> (I) <SEP> (III) <tb> (5) <SEP> DTR-CR <SEP> (IV) <SEP> (I) <tb> <SEP> (6) <SEP> DTR-GR <SEP> (III) <SEP> (I) <tb> <SEP> (7) <SEP> DTR-G/de-Ro <SEP> (I) <SEP> (VII) <tb> <SEP> (8) <SEP> DTR-GR/de-Ro <SEP> (VII) <SEP> (I) <tb> (9)DTR-B/10de-dF-CB <SEP> (I) <SEP> (VIII) <tb> (10)DTR-B/7de-dF-CB <SEP> (VIII) <SEP> (I) <tb> * For the meanings of the respective symbols, see rig. 36. (II) Determining the structure of 1-hydroxyserirubicin When l-hydroxyserirubicin (hereunder abbreviated as 1-HSR) was heated in 0.1n HCkl at 850C for 30 minutes, red orange aglycon and three sugars were produced. Based on the Rf value on silica gel TLC, mass spectrum (m/z 386 (M)+) and 4 -NMR spectrum (Fig. 34), the aglycone was identified as a2-rhodomyrinone (chem. Ber., 101, 1341-1348, 1968). The sugars as hydrolyzates were developed on silica gel TLC with a mixture of n-butanol/acetic acid/water 1:1) and subjected to color reaction with anisaldehyde-sulfuric acid. Based on the Rf values and resulting color changes, the respective sugars were found to be rhodosamine, 2-deoxyfucose and cinerulose B. Since 1-HSR gave a parent peak at m/z 1181 (M+H)+ in FD-mass spectrum, said compound is believed to have two molecules each of rhodosamine, 2-deoxyfucose and cinerulose bonded to a2-rhodom.ycinonew Table 7 classifies the chemical shifts in 13C-NMR spectrum charts for the sugar chains in 1-HSR, as compared with the data for ditrisarubicin B (J. Antibiotics, 36, 1080-1083, 1983) and serirubicin. The data suggest that the 1-HSR compounds tested have identical sugar chains. Fig. 25 shows 1H-NMR spectra for 1-HSR. This spectral analysis also supports the fact that 1-HSR compounds have the structures shown in Fig. 35. Table 7 Carbon ditrisarubicin serirubicin 1-hydroxyserirubicin 1', 1'''' 97.4, 101.9 96.6, 100.2 96.3, 100.2 2', 2'''' 29.4, 29.8 29.6 x 2 29.6 x 2 3', 3'''' 61.4 x 2 61.4, 61.6 61.4, 61.5 4', 4'''' 74.3, 74.6 74.4, 74.6 74.3, 74.5 5', 5'''' 68.3, 68.5 68.3, 68.5 68.3, 68.4 6', 6'''' 17.9, 18.1 17.9, 18.1 18.0, 18.1 NMe2 x 2 43.2, 43.3 43.28, 43.31 43.29, 43.33 1'', 1''''' 99.1 x 2 99.2 x 2 99.1 x 2 2'', 2''''' 26.9, 27.0 26.9, 27.0 26.9, 27.0 3'', 3''''' 67.3, 67.4 67.28, 67.35 67.2, 67.3 4'', 4''''' 67.0 x 2 67.0 x 2 66.9 x 2 5'', 5''''' 65.3, 65.4 65.3, 65.4 65.2, 65.3 6'', 6''''' 16.0 x 2 16.0 x 2 15.96, 16.00 1''', 1'''''' 91.6 x 2 91.6 x 2 91.6 x 2 2''', 2'''''' 63.0, 63.1 63.0, 63.1 62.97, 63.04 3''', 3'''''' 39.7, 39.8 39.7, 39.8 39.70, 39.75 4''', 4'''''' 208.1 x 2 208.1 x 2 208.1 x 2 5''', 5'''''' 77.88, 77.94 77.88, 77.94 77.88, 77.94 6''', 6'''''' 16.1, 16.2 16.1, 16.2 16.16, 16.20 R1 R2 ditrisarubicin B H OH serirubicin H H 1-hydroxyserirubicin OH H EMI35.1 io@@@gical Activity (l) Activity of inhibiting the growth of cultures leukemic cellis P 3@@8 The anthracycline compounds according to the present inve@tion inhibited the growth of the cultured cells in very low Zcses . The following table shows the concentrations (IC550) of the compounds of the present invention that could ach@eve 5D% inhibition of the growth of a two-day culture of leu@@emic cells P 388 as compared with the untreated group. Table S Compound IC50 ( g/ml) DTR-D 0.0040 DTR-E 0.0070 DTR-F 0.0038 DTR-G 0.0045 DTR-CR 0.0040 DTR-GR 0.0042 DTR-G/de-Ro 0.012 DTR-GR/de-Ro 0.020 DTR-B/10de-dF-CB 0.009 DTR-B/7de-dF-CB 0.021 1-HSR 0.012 (2) Anti-tumor effect for mice bearing Leukemia L 1210 A group of CDF1 mice were intraperitoneally transplanted with suspensions of leukemic cells L 1210 (1 x 105 cells/mouse). Immediately after the transplantation, 0.25 m± each of the test compounds was injected peritoneally into the mice for 10 days. Observation was made for 30 days, and the percent survival for each test compound was determined, with 100 representing the number of days which the control mice group administered physiclogical saline survived. The results are shown in Table 9. Table 9 EMI37.1 <tb> <SEP> Dose <SEP> Percent <SEP> survival <SEP> (%) <tb> (mg/kg/day) <SEP> DTR-D <SEP> DTR-E <SEP> DTR-F <SEP> DTR-G <SEP> 1-HSP <tb> <SEP> Toxin <tb> <SEP> 1 <SEP> - <SEP> I <SEP> - <SEP> - <SEP> 114 <tb> <SEP> 0.5 <SEP> - <SEP> - <SEP> - <SEP> - <SEP> 139 <tb> <SEP> Toxin <SEP> Toxin <tb> <SEP> 0.25 <SEP> 131 <SEP> 106 <SEP> 133 <SEP> 125 <SEP> 145 <tb> <SEP> 0.125 <SEP> 114 <SEP> 156 <SEP> 152 <SEP> 138 <SEP> 151 <tb> <SEP> 0.0625 <SEP> 142 <SEP> 163 <SEP> 133 <SEP> 163 <SEP> 127 <tb> <SEP> 0.0313 <SEP> 125 <SEP> 119 <SEP> 127 <SEP> 117 <SEP> 108 <tb> <SEP> 0.0156 <SEP> 102 <SEP> 102 <SEP> 120 <SEP> 111 <tb> <SEP> 0.0078 <SEP> 97 <SEP> 102 <SEP> 101 <SEP> 109 <tb> Production of the Compounds of the Present Invention Example 1 (1) Preparation of seed culture A medium having the following composition was used. Galactose 2% Dextrin 2% Bacto-soyton # (Difco Lab.) 1% Corn steep liquor 0.5% Calcium carbonate 0.1% pH before sterilization 7.4 A 100-ml portion of this medium was charged into a 500-ng conical flask and sterilized. The sterilized medium was inoculated with a portion of streptomyces cyaneus MG 344-hF 49 taken from a slant culture with a platinum rod. The inoculant was subjected to shake culture at 270C for 72 hrs. (2) Fermentation A medium having the following composition was used. Dextrin 3% Glucose 0.3% Toast-soya (trade name for soybean meal produced by Nissin-Seiyu Co.) 2% Cobalt chloride 0.12 aX Calcium carbonate 0.3% Fifteen liters of this medium was charged into a 30-liter jar fermenter, sterilized and inoculated with 500 mi of the seed culture prepared in (1). The inoculant was cultured at 270C for 90 hrs at 150 rpm while air was supplied at a rate of 15 liters/min, (3) Collection of ditrisarubicins The culture obtained in (2) was filtered and the pF of the filtrate was adjusted to 8,0. The so adjusted filtrate was subjected to extraction with 10 liters of butyl acetate, and the top layer of the extract was concentrated to give 20 g of an oil. The oil was dissolved in a small amount of chloroform. The solution was passed through a column packed with 100 g of silica gel ("Kiesel Gel 60" of Merck Co.) and subjected to gradient elution with a mixture of chloroform and methanol at varying chloroform to methanol ratios. The zones containing ditrisarubicin D, E, F, G and GR were concentrated to produce 230 mg of the ditrisarubicins as a red powder. Example 2 A 100-mg portion of the crude red powder obtained in Example 1 was dissolved in a small amount of chloroform and the solution was spotted on ten thin layers of silica gel ("Kiesel Gel 60 F254" of Merck Co.) that were 0.25 mm thick and 20 x 20 cm large. After development with a mixture of chloroform, methanol and conc. aqueous ammonia (100:5:0.02), separate zones for ditrisarubicin D, E, F, G and GR were collected and eluted from the silica gel with a chloroform/methanol (10:1) mixture. The so-obtained fractions were concentrated and purified by HPLC. Separation was conducted on a column (20 # x 300 mm) of "Nucleosil 5C18" (Nagel Co.) with a solvent system of acetonitrile/0.45% aq. phosphoric acid. The respective eluates were neutralized with sodium bicarbonate and extracted with chloroform. The chloroform layer was concentrated to dryness. The samples dissolved in chloroform/methanol (1:1) mixture were put on clumns (2.0 # x 28 n) of "Cephadex LH-20" that had been equilibratec with the same solvent mixture. Upon elution with the same solvent mixture and concentration under vacuum to dryness, ditrisarubicin D, E, F, G and GR were obtained in respective amounts of 32.0 mg, 31.5 mg, 30.5 mg, 65.5 mg and 67.5 mg. Each of these samples was found to consist of a single component upon analysis by TLC on silica gel plate and high-pressure liquid chromatography using "Nucleosil 5C18". Example 3 Ditrisarubicin 3 (50 mg) was dissolved in 5 mQ 0.1N HCl and the solution was left to stand at 700C for 15 minutes. The solution was put on a column packed with 10 g of silica gel ("Riesel Gel 50" of Merck Co.). which was washed with 50 mQ of chloroform/methanol (100:1) and eluted with chloroform/methanol (100:5). The resulting eluates were concentrated and spotted on 10 thin layers of silica gel ("Kiesel Gel 60 F25 " of Merck Co.) that were 0.25 mm thick and 20 x 20 cm large. After development with a mixture of chloroform, methanol and conc. aqueous ammonia (100:10:0.05), the separating ditrisarubicin B/7 de-dF-CB and B/10 de-dF-CB ware collected and eluted with a chloroform/methanol (1:1) mixture. The so-obtained fractions were concentrated and purified by HPLC. Separation was conducted on a column (20 # x 300 mm) of "Nucleosil 5C18 (Nagel Co.) with a solvent svstem of acetonitrile/0.45% aq. phosphoric acid. The respective eluates were neutralized with sodium. bicarbonate and extracted with chloroform. The chloroform layer was concentrated to dryness. The samples dissolved in a mixture of chloroform/methanol (1:1) were put on columns (2.0 # X 28 cm) of "Cephadex LH-20" that had been equilibrated with the same solvent mixture. Upon elution with the same solvent mixture and concentration under vacuum to dryness, ditrisarubicin B/7 de-dF-CB and B/10 de-dF-CB were obtained in respective amounts of 3.2 mg and 4.7 mg. Each of these samples was found to consist of a single component upon analysis by TLC on silica gel plate and high-pressure liquid chromatography using "Nucleosil SC18". Example 4 Fifty milligrams of ditrisarubicin G and GR was reacted with 0.lN HCl at 300C for 20 minutes. After extraction, the extracts were subjected to silica gel chromatography. After removing DTR-G or DTR-GR with CHCQ3/MeOH (100:3) mixture, elution was conducted with CHCR3/MeOH (100:5) and the respective eluates were concentrated under vacuum to dryness. Solutions of the residues were passed through a column of "Cephadex W-20" and eluted with CHCl3/MeOH (1:1) mixture to obtain DTR-G/de-Ro and DTR-GR/de-Ro in respective amounts of 25 mg and 15 mg. Upon analysis by TLC and HPLC, each of the samples thusly obtained was found to consist of a single component. Example 5 Eight hundred mg of a mixture of DTR-3, C, CR, serirubicin (SR) and l-hydroxyserirubicin (HSR) was dissolved in a small amount of chloroform, and the resulting solution was spotted on 80 thin layers of silica gel (Kiesel Gel 60 F254" of Merck Co.) that were 0.25 mm thick and 20 x 20 cm larger. After development with a mixture of chloroform, methanol and conc. aqueous ammonia (100:5:0.02), zones for DTR-C, SR and HSR were collected and eluted with a chloroform/methanol (10:1) mixture. After concentration to dryness, solutions of the residues were spotted on 20 thin layers of the same silica gel and developed with a mixture of ethyl acetate, methanol and conc. aqueous ammonia (25:1:0.08). The spots were collected, eluted, concentrated and subjected to another TLC on three thin layers of the same silica gel, followed by elution with a mixture of chloroform, methanol and conic. aqueous ammonia (100:5:0.02) in order to remove the small amount of residual DTR-B. After concentrating the eluates to dryness, an HSR fraction was obtained by column chromatography on "Cephadex LH-20" (eluant: MeOH) and concentrated under vacuum to dryness so as to obtain 13.7 mg of HSR as a red orange powder. The thusly obtained sample was found to consist of a single component upon analysis by TLC and HPLC (reverse phase). Brief Description of the Drawings Figs. 1 to Z5 are IR, NMR and UV spectra charts for compounds (1) to (11), as specified below: Fig. No. Spectrum Compound 1 IR (1) 2 NMR (1) 3 IR (2) 4 NMR (2) 5 IR (3) 6 NMR (3) 7 UV (4) 8 IR (4) 9 NMR (4) 10 UV (5) 11 IR (5) 12 NMR (5) 13 IR (6) 14 NMR (6) Fig. No. Spectrum Compound 15 IR (7) 16 NMR (7) 17 IR (8) 18 NMR (8) 19 IR (9) 20 NI4R (9) 21 IR (10) 22 NMR (10) 23 UV (11) 24 IR (il) 25 NMR (11) Fig. 26 is a flowsheet showing an outline for the procedures of determining the structures of the anthracycline compounds of the present invention. Figs. 27 to 34 are NMR spectrum charts for the decomposition products obtained during the process for determining the structures of the anthracycline compounds of the present invention. Fig. 35 shows the structures of compound (11), and Fig. 36 shows the structures of the respective sugars in that compound.

Claims: Claims: 1. A compound of the formula I or an acid addition salt thereof EMI45.1 wherein R1 is hydrogen, R2 is hydroxy and R3 and R4 represent any of the following ten sugar combinations: R3 (I) (V) (11) (11) (I) (VI) (I) (III) (IV) (I) (III) (I) (I) (VII) (VII) (I) (I) (vIII) (VIII) (I) or R1 is hydroxy, R2 is hydrogen and R3 and R4 represent each the sugar combination (I), wherein the symbols (I) to (VIII) represent the following sugar chains: (I) RN-dF-CB (II) RN-dF-CA EMI46.1 (III) RN-dF-Ro (IV) RN-Ro-Ac EMI46.2 (V) RN-Ro-CA (VI) RN-Ro-Ro EMI47.1 (VII) RN-dF (VIII) EMI47.2 (RN: rhodosamine, dF: 2-deoxyfucose, CB: cinerulose B, CA: cinerulose A, Ac: aculose, Ro: rhodinose). 2. A process for the preparation of compounds of the formula I or an acid addition salt thereof EMI48.1 wherein R1 is hydrogen, R2 is hydroxy and R3 and R4 represent any of the following ten sugar combinations: R3 R (I) (V, (II) (II) (I) (VI) (I) (III) (iv) (I) (III) (I) (I) (VII) (VII) (I) (i) (VIII) (VIII) (I) or R1 is hydroxy, R2 is hydrogen and R. and R4 represent each the sugar combination (I), wherein the symbols (I) to (VIII) represent the following sugar chains: (I) RN-dF-CB (II) RN-dF-CA EMI49.1 (III) RN-dF-Ro (IV) RN-Ro-Ac EMI49.2 (V) RN-Ro-CA (VI) aN-Ro-Ro EMI50.1 (VII) RN-dF (VIII) RN EMI50.2 (RN: rhodosamine, dF: 2-deoxyfucose, CB: cinerulose B, CA: cinerulose A, Ac: aculose, Ro: rhodinose). which comprises cultivating a strain of the genus streptomyces being capable of producing the anthracy dine compounds of the present invention, in a suita ble culture medium under aerobic conditions and sub sequently recovering the compounds of the formula I from the cultured medium. 3. The process as claimed in claim 2 wherein the culture meiium is a liquid submerged culture consist of nutritional carbon sources, nitrogen sources and op tionally inorganic salts and/or antifoaming agents at a temperature from 20 to 35"C and the produced compounds are recovered from the cultured medium by usual extrac tion or adsorption methods. 4. 2he process as defined in clains 2 and 3 wherein the strain Streptornyces cyaneus TIG 344-hF 49 (FER3I BP-314) was used. 5. A pharmaceutical composition containing as its active ingredient a compound of the formula I or an acid ad dition salt thereof as defined in claim 1 in associa tion with a pharmaceutically acceptable carrier. 6. The use of a compound of the formula I or an acid ad dition salt thereof as defined in claim 1 for the preparation of a medicament having anti-tumor activi ties. Cleims for Austria: 1. . A process for t the preparation of compounds of the formula I or an acid addition slt thereof EMI52.1 wherein P1 is hydrogen, R2 is hydroxy and R3 and R4 represent any of the following ten sugar combinations: R3 R4 (I) (V) (II) (II) (I) (VI) (I) (III) (IV) (I) (III) (I) (I) (VII) (VII) (I) (I) (VIII) (VIII) (I) or R1 is hydroxy, R2 is hydrogen and R3 and R4 represent each the sugar combination (I), wherein the symbols (I) to (VIII) represent the following sugar chains: (I) RN-dF-CB (II) RN-dF-CA EMI53.1 (III) RN-dF-Ro (IV) RN-Ro-Ac EMI53.2 (V) RN-Ro-CA (VI) RN-Ro-Ro EMI54.1 (VII) RN-dF (VIII) RN EMI54.2 (RN: rhodosamine, dF: 2-deoxyfucose, CB: cinerulose B, CA: cinerulose A, Ac: aculose, Ro: rhodinose). which comprises cultivating a strain of the genus streptomyces being capable of producing the anthracy cline compounds of the present invention, in a suita ble culture medium under aerobic conditions and sub sequently recovering %;. compounds of the formula I from the cultured medi@@ 2. The process as claimed in claim 2 wherein the ciilture medium is a liquid submerged culture consisting of nutritional carbon sources, nitrogen sources and op tionally inorganic salts and/or antiloaning agents at a temperature from 20 to 35 C and the produced compounds are recovered from the cultured medium by usual extrac tion or adsorption methods. 3. The process as defined in claims 2 and 3 wherein the strain Streptomyces cyaneus MG 344-hF 49 (FBRM BP-314) was used.

Inventors: HAMADA, MASA, IMOTO, MASAYA, NAGANAWA, HIROSHI, SAWA, TSUTOMU, TAKEUCHI, TOMIO, UCHIDA, TAKESHI, UMEZAWA, HAMAO, PROF.
Applicants: MICROBIAL CHEMISTRY RESEARCH FOUNDATION
Application year: 1985
Main classification: C07H15
IPC codes: A61K31, C12P19, C07H15, A61P31